These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

598 related items for PubMed ID: 14634792

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961).
    Panosyan EH, Grigoryan RS, Avramis IA, Seibel NL, Gaynon PS, Siegel SE, Fingert HJ, Avramis VI.
    Anticancer Res; 2004; 24(2C):1121-5. PubMed ID: 15154634
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
    Nath CE, Dallapozza L, Eslick AE, Misra A, Carr D, Earl JW.
    Biomed Chromatogr; 2009 Feb; 23(2):152-9. PubMed ID: 18823071
    [Abstract] [Full Text] [Related]

  • 6. Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
    Vieira Pinheiro JP, Wenner K, Escherich G, Lanvers-Kaminsky C, Würthwein G, Janka-Schaub G, Boos J.
    Pediatr Blood Cancer; 2006 Jan; 46(1):18-25. PubMed ID: 15929133
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
    Schrey D, Borghorst S, Lanvers-Kaminsky C, Hempel G, Gerss J, Möricke A, Schrappe M, Boos J.
    Pediatr Blood Cancer; 2010 Jul 01; 54(7):952-8. PubMed ID: 20108339
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
    Jarrar M, Gaynon PS, Periclou AP, Fu C, Harris RE, Stram D, Altman A, Bostrom B, Breneman J, Steele D, Trigg M, Zipf T, Avramis VI.
    Pediatr Blood Cancer; 2006 Aug 01; 47(2):141-6. PubMed ID: 16425271
    [Abstract] [Full Text] [Related]

  • 10. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
    Chen FX, Cui YQ, Wu ZL, Ye TZ, Lai YH, Zou YW, Lu CY, Guan JM, Wei FG, Zhang H.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb 01; 26(2):100-2. PubMed ID: 15921627
    [Abstract] [Full Text] [Related]

  • 11. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
    Domenech C, Thomas X, Chabaud S, Baruchel A, Gueyffier F, Mazingue F, Auvrignon A, Corm S, Dombret H, Chevallier P, Galambrun C, Huguet F, Legrand F, Mechinaud F, Vey N, Philip I, Liens D, Godfrin Y, Rigal D, Bertrand Y.
    Br J Haematol; 2011 Apr 01; 153(1):58-65. PubMed ID: 21332712
    [Abstract] [Full Text] [Related]

  • 12. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
    Rizzari C, Citterio M, Zucchetti M, Conter V, Chiesa R, Colombini A, Malguzzi S, Silvestri D, D'Incalci M.
    Haematologica; 2006 Jan 01; 91(1):24-31. PubMed ID: 16434367
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Population pharmacokinetics of native Escherichia coli asparaginase.
    Borghorst S, Pieters R, Kuehnel HJ, Boos J, Hempel G.
    Pediatr Hematol Oncol; 2012 Mar 01; 29(2):154-65. PubMed ID: 22376019
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
    Boos J.
    Int J Clin Pharmacol Ther; 1997 Mar 01; 35(3):96-8. PubMed ID: 9088996
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preliminary in vivo evaluation of the protein transduction domain-modified ATTEMPTS approach in enhancing asparaginase therapy.
    Li YT, Kwon YM, Spangrude GJ, Liang JF, Chung HS, Park YJ, Yang VC.
    J Biomed Mater Res A; 2009 Oct 01; 91(1):209-20. PubMed ID: 18814276
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.